

CORRECTION

Open Access



Correction to: Artemisinin derivatives inactivate cancer-associated fibroblasts through suppressing TGF- β signaling in breast cancer

Yuyuan Yao^{1†}, Qinglong Guo^{1†}, Yue Cao¹, Yangmin Qiu¹, Renxiang Tan², Zhou Yu¹, Yuxin Zhou¹ and Na Lu^{1*}

Correction to: J Exp Clin Cancer Res (2018) 37: 282
<https://doi.org/10.1186/s13046-018-0960-7>

In the original publication of this article [1], Fig. 3 is wrong, but does not affect discussions and conclusions drawn in the article.

The corrected Fig. 3 is shown below:

Author details

¹State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, People's Republic of China. ²State Key Laboratory Cultivation Base for TCM Quality and Efficacy, Nanjing University of Chinese Medicine, 138 Xinlin Road, Nanjing 210023, People's Republic of China.

Published online: 05 November 2019

Reference

1. Yao Y, et al. Artemisinin derivatives inactivate cancer-associated fibroblasts through suppressing TGF- β signaling in breast cancer. *J Exp Clin Cancer Res*. 2018;37:282. <https://doi.org/10.1186/s13046-018-0960-7>.

* Correspondence: nalu@cpu.edu.cn

[†]Yuyuan Yao and Qinglong Guo contributed equally to this work.

¹State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, People's Republic of China

Full list of author information is available at the end of the article






Fig. 3.